Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

GxP News
gxpnews.net > en > 2026 > 08 > russia-approves-camrelizumab-for-triple%E2%80%91negative-breast-cancer-boosting-treatment-options

Russia approves camrelizumab for triple???negative breast cancer, boosting treatment options | News

3+ week, 3+ day ago   (320+ words) The indication expansion was based on results from the international Phase III CamRelief clinical trial. Adding the immunotherapy to standard chemotherapy increased the pathological complete response rate in TNBC patients from 44.7% to 56.8%. According to clinical‑economic modelling data, introducing camrelizumab…...